| Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire M van Leeuwen, JM Kieffer, TE Young, MA Annunziata, V Arndt, JI Arraras, ... Journal of Cancer Survivorship 17 (4), 1111-1130, 2023 | 15 | 2023 |
| Anticancer Activity of Electron‐Deficient Metal Complexes against Colorectal Cancer in vitro Models M Azmanova, J Soldevila‐Barreda, H Bani Hani, RM Lord, A Pitto‐Barry, ... ChemMedChem 14 (22), 1887-1893, 2019 | 8 | 2019 |
| Guideline-based, multi-gene panel germline genetic testing for at-risk patients with breast cancer H Abdel-Razeq, L Abujamous, K Al-Azzam, H Abu-Fares, H Bani Hani, ... Breast Cancer: Targets and Therapy, 1-10, 2023 | 2 | 2023 |
| Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives H Abdel-Razeq Frontiers in Oncology 13, 2023 | 2 | 2023 |
| Implementation of universal pan-cancer germline genetic testing in an Arab population: The jordanian exploratory cancer fenetics (Jo-ECAG) study. H Abdel-Razeq, SM Nielsen, A Tbakhi, H Bani Hani, B Sharaf, ... Journal of Clinical Oncology 41 (16_suppl), 10591-10591, 2023 | 1 | 2023 |
| Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo‐ECAG) ovarian study H Abdel‐Razeq, K Al‐Azzam, S Elemian, H Abu‐Fares, A Abu Sheikha, ... Molecular Genetics & Genomic Medicine 11 (4), e2125, 2023 | 1 | 2023 |
| Abstract PO5-08-01: Investigating the Link between APC I1307K Mutation and Breast Cancer in Arab Population B Sharaf, HB Hani, A Zayed, M Barbar, A Hushki, R Abdel-Razeq, M Titi, ... Cancer Research 84 (9_Supplement), PO5-08-01-PO5-08-01, 2024 | | 2024 |
| Germline Genetic Mutations in Adult Patients with Sarcoma: Insight into the Middle East Genetic Landscape R Abu-Hijlih, B Sharaf, S Salah, H Bani Hani, M Alqaisieh, A Alzibdeh, ... Cancers 16 (9), 1668, 2024 | | 2024 |
| Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer A Hajahjeh, HB Hani, H Abdel-Razeq Frontiers in Oncology 14, 2024 | | 2024 |
| 2349P Patterns and frequency of pathogenic germline variants (PGVs) among non-western young male patients with cancer: The Jordanian exploratory cancer genetics (Jo-ECAG) study HB Hani, H Abu-Fares, S Abdel-Razeq, BS Sharaf, H Abu-Jaish, I Hamad, ... Annals of Oncology 34, S1195, 2023 | | 2023 |
| Clinical implications of universal germline testing in breast cancer patients in an Arab population: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) study. H Abdel-Razeq, SM Nielsen, B Sharaf, H Bani Hani, EM Russell, B Heald, ... Journal of Clinical Oncology 41 (16_suppl), e22535-e22535, 2023 | | 2023 |
| Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression M Horani, H Abdel-Razeq Frontiers in Oncology 13, 2023 | | 2023 |
| Patterns and prevalence of pathogenic germline mutations using multi-gene panel testing in patients with ovarian cancer: The Jordanian Exploratory Cancer Genetics (Jo-ECAG … K Al-Azzam, H Abu-Fares, A Abu Sheikha, L Abujamous, M Alkyam, ... Journal of Clinical Oncology 40 (16_suppl), e17593-e17593, 2022 | | 2022 |
| Next Generation Selective Estrogen Receptor Degraders (SERDs) in Postmenopausal Women with Advanced-Stage Hormone Receptors-Positive, HER2-Negative Breast Cancer B Sharaf, A Alhajahjeh, H Bani Hani, H Abdel-Razeq Frontiers in Oncology 14, 1385577, 0 | | |
